BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kifle ZD, Ayele AG, Enyew EF. Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment. J Environ Public Health 2021;2021:6631721. [PMID: 33953756 DOI: 10.1155/2021/6631721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Chavda VP, Prajapati R, Lathigara D, Nagar B, Kukadiya J, Redwan EM, Uversky VN, Kher MN, Rajvi P. Therapeutic monoclonal antibodies for COVID-19 management: an update. Expert Opin Biol Ther 2022. [PMID: 35604379 DOI: 10.1080/14712598.2022.2078160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Basu D, Chavda VP, Mehta AA. Therapeutics for COVID-19 and post COVID-19 complications: An update. Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100086] [Reference Citation Analysis]
3 Joglekar S, Iyer SS, Parate R, Khobragade AA, Patil R, Bhushan S, Halnor DM, Rajadhyaksha GC, Parmar K, Dhawan S, Mehta S, Joshi SR. Efficacy and Safety of a Phytopharmaceutical Drug Derived from Cocculus hirsutus in Adults with Moderate COVID-19: a Phase 2, Open-label, Multicenter, Randomized Controlled Trial. Infect Dis Ther 2022. [PMID: 35179709 DOI: 10.1007/s40121-022-00604-0] [Reference Citation Analysis]
4 Vimberg V. Teicoplanin-A New Use for an Old Drug in the COVID-19 Era? Pharmaceuticals (Basel) 2021;14:1227. [PMID: 34959628 DOI: 10.3390/ph14121227] [Reference Citation Analysis]
5 Chavda VP, Kapadia C, Soni S, Prajapati R, Chauhan SC, Yallapu MM, Apostolopoulos V. A global picture: therapeutic perspectives for COVID-19. Immunotherapy. [DOI: 10.2217/imt-2021-0168] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
6 Barghash RF, Fawzy IM, Chandrasekar V, Singh AV, Katha U, Mandour AA. In Silico Modeling as a Perspective in Developing Potential Vaccine Candidates and Therapeutics for COVID-19. Coatings 2021;11:1273. [DOI: 10.3390/coatings11111273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Sonkar C, Doharey PK, Rathore AS, Singh V, Kashyap D, Sahoo AK, Mittal N, Sharma B, Jha HC. Repurposing of gastric cancer drugs against COVID-19. Comput Biol Med 2021;137:104826. [PMID: 34537409 DOI: 10.1016/j.compbiomed.2021.104826] [Reference Citation Analysis]
8 Asano T, Chelvanambi S, Decano JL, Whelan MC, Aikawa E, Aikawa M. In silico Drug Screening Approach Using L1000-Based Connectivity Map and Its Application to COVID-19. Front Cardiovasc Med 2022;9:842641. [DOI: 10.3389/fcvm.2022.842641] [Reference Citation Analysis]
9 Mortezaei Z, Mohammadian A, Tavallaei M. Variations of SARS-CoV-2 in the Iranian population and candidate putative drug-like compounds to inhibit the mutated proteins. Heliyon 2022;8:e09910. [PMID: 35847618 DOI: 10.1016/j.heliyon.2022.e09910] [Reference Citation Analysis]
10 Garg S, Singh VK, Sonkar SC, Kelkar H, Singh S, Garg S, Arya M, Husain F, Chandra L, Chitkara A, Talukdar T, Goswami B, Koner BC. Pattern of serum protein capillary electrophoretogram in SARS- CoV-2 infection. Clin Chim Acta 2022;527:11-6. [PMID: 35007527 DOI: 10.1016/j.cca.2022.01.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ayyar P, Subramanian U. Repurposing – second life for drugs. PHAR 2022;69:51-9. [DOI: 10.3897/pharmacia.69.e72548] [Reference Citation Analysis]